Diffuse intrinsic pontine glioma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:497188C72.8
Who is this for?
Show terms as
1FDA treatments27Active trials48Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Diffuse intrinsic pontine glioma, often called DIPG, is a type of brain tumor that grows in the brainstem — specifically in a region called the pons. The pons is a critical part of the brain that controls many basic body functions, including breathing, heart rate, swallowing, eye movement, and balance. Because the tumor grows in a diffuse pattern, meaning it spreads throughout the tissue rather than forming a single lump, it cannot be safely removed with surgery. DIPG mainly affects children, typically between the ages of 5 and 10, though it can occur in younger children and teenagers as well. The tumor grows quickly and puts pressure on the brainstem, causing a range of serious symptoms. The most common early signs include problems with facial muscle control, difficulty walking, and double vision. As the tumor grows, children may develop weakness on one side of the body, trouble swallowing, and problems with speech. Treatment options for DIPG are very limited. Radiation therapy is the current standard of care and can temporarily shrink the tumor and relieve symptoms, but it does not cure the disease. Chemotherapy has not been shown to significantly improve outcomes in most cases. In recent years, researchers have discovered that most DIPG tumors carry a specific genetic change called the H3 K27M mutation, which has opened new doors for targeted therapies. Clinical trials are actively exploring new treatments, including ONC201, which has shown early promise for tumors with this mutation.

Also known as:

Key symptoms:

Double vision or crossed eyesDrooping eyelid or facial weakness on one sideDifficulty walking or loss of balanceWeakness or clumsiness in arms or legsTrouble swallowing or changes in speechHeadaches, especially in the morningNausea and vomitingFatigue and low energyChanges in behavior or personalityDifficulty controlling eye movementsHearing changesBreathing problems in advanced stages

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Dec 2026Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

M.D. Anderson Cancer Center — PHASE1

TrialNOT YET RECRUITING
Apr 2026PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Washington University School of Medicine — PHASE1, PHASE2

TrialNOT YET RECRUITING
Mar 2026H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Shenzhen Geno-Immune Medical Institute — PHASE1, PHASE2

TrialRECRUITING
Mar 2026Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

Nationwide Children's Hospital — PHASE2

TrialNOT YET RECRUITING
Jul 2025ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Nationwide Children's Hospital — PHASE2

TrialRECRUITING
Mar 2024CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

OX2 Therapeutics — PHASE1

TrialRECRUITING
Mar 2024Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

Chulalongkorn University — PHASE1

TrialRECRUITING
Oct 2023RE-irradiation of Diffuse MIdline Glioma paTients

Rigshospitalet, Denmark — NA

TrialNOT YET RECRUITING
Aug 2023CAR T Cells to Target GD2 for DMG

University College, London — PHASE1

TrialRECRUITING
Jun 2023FUS Etoposide for DMG

Columbia University — PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Modeyso

dordaviprone· Chimerix, Inc.Orphan Drug

Treatment of adult and pediatric patients 2 years of age and older with H3 K27M-mutant diffuse glioma after prior radiotherapy. Dordaviprone is the first FDA-approved drug for this tumor type.

Clinical Trials

20 recruitingView all trials with filters →
Phase 31 trial
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Phase 3
Actively Recruiting
PI: Jacques GRILL, MD, PhD (Gustave Roussy, Cancer Campus, Grand Paris) · Sites: Aarhus; Copenhagen +48 more
Phase 24 trials
A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma
Phase 2
Actively Recruiting
PI: Rahul Krishnatry, Dr (Tata Memorial Hospital) · Sites: Mumbai, Maharashtra · Age: 318 yrs
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Phase 2
Actively Recruiting
PI: David S. Ziegler, MD, FRACP (Sydney Children's Hospitals Network) · Sites: Aurora, Colorado; Washington D.C., District of Columbia +18 more · Age: 039 yrs
Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study
Phase 2
Actively Recruiting
PI: Roman O. Kowalchuk, MD (Mayo Clinic in Rochester) · Sites: Phoenix, Arizona; Rochester, Minnesota · Age: 199 yrs
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Phase 2
Actively Recruiting Prior treatment eligible
PI: Sabine Mueller, MD, PhD (University of California, San Francisco) · Sites: Birmingham, Alabama; Los Angeles, California +18 more · Age: 239 yrs
Phase 16 trials
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
Phase 1
Active
PI: Ralph Salloum (Pediatric Brain Tumor Consortium) · Sites: Los Angeles, California; Palo Alto, California +10 more · Age: 621 yrs
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Phase 1
Active
PI: Maryam Fouladi, MD (Nationwide Children's Hospital) · Sites: Aurora, Colorado; Washington D.C., District of Columbia +8 more · Age: 021 yrs
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Phase 1
Actively Recruiting
PI: Ashley Plant-Fox, MD (Ann and Robert H. Lurie Children's Hospital) · Sites: Orange, California; Chicago, Illinois +1 more · Age: 018 yrs
Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma
Phase 1
Actively Recruiting
PI: Hongwei Zhang, Prof. (Capital Medical University) · Sites: Beijing, Beijing Municipality · Age: 118 yrs
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1
Actively Recruiting
PI: Sabine Mueller, MD, PhD (University of California, San Francisco) · Sites: San Francisco, California; Atlanta, Georgia +4 more · Age: 221 yrs
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
Phase 1
Actively Recruiting
PI: Hongwei Zhang, Prof. (Capital Medical University) · Sites: Beijing, Beijing Municipality · Age: 118 yrs
Other3 trials
International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
Actively Recruiting
PI: Lindsey Hoffman, DO (Phoenix Children's Hospital) · Sites: Cincinnati, Ohio
Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
Actively Recruiting
PI: Javad Nazarian, PhD (Children's National Research Institute) · Sites: Washington D.C., District of Columbia · Age: 021 yrs
International HIT-MED Registry (I-HIT-MED)
Actively Recruiting
PI: Stefan Rutkowski, Prof. (Universitätsklinikum Hamburg-Eppendorf) · Sites: Aachen; Augsburg +55 more

Specialists

Showing 25 of 48View all specialists →
EM
Eric Bouffet, MD
Los Angeles, California
Specialist

Rare Disease Specialist

PI on 2 active trials
SM
Sabine Mueller, MD
SAN FRANCISCO, CA
Specialist
PI on 1 active trial
UM
Ute Bartels, MD
Specialist
PI on 1 active trial
AM
Adam Green, MD
Specialist
PI on 1 active trial1 Diffuse intrinsic pontine glioma publication
PM
Piti Techavichit, MD
HOUSTON, TX
Specialist
PI on 1 active trial
WZ
Wafik T Zaky
HOUSTON, TX
Specialist
PI on 1 active trial2 Diffuse intrinsic pontine glioma publications
LD
Lindsey Hoffman, DO
Phoenix, Arizona
Specialist

Rare Disease Specialist

PI on 2 active trials5 Diffuse intrinsic pontine glioma publications
MM
Maryam Fouladi, MD
COLUMBUS, OH
Specialist
PI on 10 active trials
SM
Stergios Zacharoulis, MD
LONDON, UK
Specialist
PI on 1 active trial
SP
Sabine Mueller, MD, PhD
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 9 active trials
RS
Ralph Salloum
BOSTON, MA
Specialist
PI on 2 active trials4 Diffuse intrinsic pontine glioma publications
ZP
Zwi N Berneman, MD, PhD
Specialist
PI on 3 active trials
SP
Stanislaw R. Burzynski, MD, PhD
HOUSTON, TX
Specialist
PI on 29 active trials
SM
Sabine Mueller, MD, PhD, MAS
SAN FRANCISCO, CA
Specialist
PI on 8 active trials
JM
Julie Krystal, MD
NEW HYDE PARK, NY
Specialist
PI on 1 active trial
SM
Sylvain Baruchel, MD
Specialist
PI on 2 active trials
TM
Tobey MacDonald, MD
WASHINGTON, DC
Specialist
PI on 3 active trials
HM
Heather McCrea, MD
MIAMI, FL
Specialist
PI on 1 active trial
JP
Jaime Gallego, MD, PhD
Specialist
PI on 1 active trial
LM
Luca Szalontay, MD
WASHINGTON, DC
Specialist
PI on 1 active trial1 Diffuse intrinsic pontine glioma publication
MM
Mariko D. DeWire-Schottmiller, MD
CINCINNATI, OH
Specialist
PI on 1 active trial
JM
John W Glod, M.D.
NEW BRUNSWICK, NJ
Specialist
PI on 4 active trials
LM
Luke E Pater, MD
CINCINNATI, OH
Specialist
PI on 1 active trial1 Diffuse intrinsic pontine glioma publication
MM
Mark Souweidane, MD
NEW YORK, NY
Specialist
PI on 1 active trial
AG
Adam L Green
Specialist
PI on 1 active trial63 Diffuse intrinsic pontine glioma publications

Treatment Centers

8 centers
⚗️ Trial Site

Children's Hospital of Philadelphia

📍 Philadelphia, Pennsylvania

👤 Study Director

👤 Richard Neibeger, MD

⚗️ Trial Site

Ann & Robert H. Lurie Children's Hospital of Chicago

📍 Chicago, Illinois

⚗️ Trial Site

Nationwide Children's Hospital

📍 Columbus, Ohio

⚗️ Trial Site

University of Michigan

📍 Ann Arbor, Michigan

👤 Janssen Research & Development, LLC Clinicaltrial

⚗️ Trial Site

University of Alabama at Birmingham

📍 Birmingham, Alabama

⚗️ Trial Site

Johns Hopkins University

📍 Baltimore, Maryland

⚗️ Trial Site

Seattle Children's Hospital

📍 Seattle, Washington

👤 Study Director

👤 Richard Neibeger, MD

⚗️ Trial Site

Children's National Hospital

📍 Washington D.C., District of Columbia

Travel Grants

No travel grants are currently matched to Diffuse intrinsic pontine glioma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Diffuse intrinsic pontine gliomaForum →

No community posts yet. Be the first to share your experience with Diffuse intrinsic pontine glioma.

Start the conversation →

Latest news about Diffuse intrinsic pontine glioma

Disease timeline:

New recruiting trial: Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

New recruiting trial: Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

A new clinical trial is recruiting patients for Diffuse intrinsic pontine glioma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Does my child's tumor have the H3 K27M mutation, and what does that mean for treatment options?,Are there any clinical trials that my child might be eligible for?,What are the goals of radiation therapy, and what side effects should we expect?,When should we involve palliative care, and what does that involve?,How will we know if the tumor is responding to treatment or growing again?,What support services — such as physical therapy, speech therapy, or psychological support — are available for our family?,Should we seek a second opinion at a specialized DIPG center?

Common questions about Diffuse intrinsic pontine glioma

What is Diffuse intrinsic pontine glioma?

Diffuse intrinsic pontine glioma, often called DIPG, is a type of brain tumor that grows in the brainstem — specifically in a region called the pons. The pons is a critical part of the brain that controls many basic body functions, including breathing, heart rate, swallowing, eye movement, and balance. Because the tumor grows in a diffuse pattern, meaning it spreads throughout the tissue rather than forming a single lump, it cannot be safely removed with surgery. DIPG mainly affects children, typically between the ages of 5 and 10, though it can occur in younger children and teenagers as well

How is Diffuse intrinsic pontine glioma inherited?

Diffuse intrinsic pontine glioma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Diffuse intrinsic pontine glioma typically begin?

Typical onset of Diffuse intrinsic pontine glioma is childhood. Age of onset can vary across affected individuals.

Are there clinical trials for Diffuse intrinsic pontine glioma?

Yes — 20 recruiting clinical trials are currently listed for Diffuse intrinsic pontine glioma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Diffuse intrinsic pontine glioma?

25 specialists and care centers treating Diffuse intrinsic pontine glioma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.